Alessandro Bonardi, PhD
Post-Doctorate Fellow at the NEUROFARBA Department, University of Florence, Italy. Degree in Pharmaceutical Chemistry and Technology in 2016, PhD cum laude in Medicinal Chemistry in 2021 from the University of Florence, Italy. Alessandro Bonardi developed multidisciplinary expertise, falling in SSD CHIM/08, in:
1. Rational design and synthesis of small molecules of pharmaceutical interest. His main research topics are the metalloenzymes carbonic anhydrases (CAs) and the discovery of modulators for biomedical purposes. He achieved excellent knowledge of organic chemistry used for the synthesis of a multitude of CA inhibitory scaffolds and molecular hybrids.
2. In silico structure-based drug design and study of the action mechanisms of small molecules toward their biological target. He has a documented experience in the use of computational chemistry, bioinformatics and molecular graphics for the computationally driven design of bioactive molecules and for deciphering their mechanism of action, adopting a plethora of molecular modeling techniques.
3. In vitro studies for the biological evaluation of the inhibitors/activators activity on CA isoforms, using the stopped-flow kinetic technique. He also performed the activity characterization of new CAs and spectrophotometry studies to detect CA-catalyzed reactions.
Alessandro Bonardi, PhD
Post-Doctorate Fellow at the NEUROFARBA Department, University of Florence, Italy. Degree in Pharmaceutical Chemistry and Technology in 2016, PhD cum laude in Medicinal Chemistry in 2021 from the University of Florence, Italy. Alessandro Bonardi developed multidisciplinary expertise, falling in SSD CHIM/08, in:
1. Rational design and synthesis of small molecules of pharmaceutical interest. His main research topics are the metalloenzymes carbonic anhydrases (CAs) and the discovery of modulators for biomedical purposes. He achieved excellent knowledge of organic chemistry used for the synthesis of a multitude of CA inhibitory scaffolds and molecular hybrids.
2. In silico structure-based drug design and study of the action mechanisms of small molecules toward their biological target. He has a documented experience in the use of computational chemistry, bioinformatics and molecular graphics for the computationally driven design of bioactive molecules and for deciphering their mechanism of action, adopting a plethora of molecular modeling techniques.
3. In vitro studies for the biological evaluation of the inhibitors/activators activity on CA isoforms, using the stopped-flow kinetic technique. He also performed the activity characterization of new CAs and spectrophotometry studies to detect CA-catalyzed reactions.